Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7Z418
UPID:
KCNKI_HUMAN
Alternative names:
TWIK-related individual potassium channel; TWIK-related spinal cord potassium channel
Alternative UPACC:
Q7Z418; Q5SQQ8
Background:
Potassium channel subfamily K member 18, also known as TWIK-related individual potassium channel, plays a crucial role in maintaining the resting membrane potential and is involved in the pain sensation process. It is activated by calcium signals and G(q)-protein coupled receptor pathways, and inhibited by unsaturated fatty acids and arachidonic acid.
Therapeutic significance:
The protein's link to Migraine with or without aura 13, a condition characterized by severe headaches and neurological symptoms, highlights its potential as a target for migraine therapies. Understanding the role of Potassium channel subfamily K member 18 could open doors to potential therapeutic strategies.